BAXTER INTL INC shareholders Q2 2022

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q2 2022
NameSharesValueWeighting ↓
NUANCE INVESTMENTS, LLC 5,758,247$369,852,0007.34%
Soditic Asset Management LLP 147,620$9,482,0007.29%
Veritas Asset Management LLP 11,426,694$733,937,0005.48%
GENERATION INVESTMENT MANAGEMENT LLP 13,018,264$836,163,0004.56%
Boothe Investment Group, Inc. 78,568$5,145,0004.34%
Glenview Capital Management 2,173,019$139,573,0003.49%
Dash Acquisitions Inc. 85,816$5,512,0003.01%
Dundas Partners LLP 417,608$26,823,0002.90%
PRAGMA GESTAO DE PATRIMONIO LTD 60,000$3,8542.88%
PENSIOENFONDS RAIL & OV 1,205,957$77,808,0002.80%
TSFG, LLC 100,845$6,477,0002.78%
Haverford Financial Services, Inc. 145,563$9,350,0002.72%
Cincinnati Specialty Underwriters Insurance CO 96,500$6,198,0002.67%
STONERIDGE INVESTMENT PARTNERS LLC 69,668$4,475,0002.46%
Sivik Global Healthcare LLC 65,000$4,175,0002.37%
CINCINNATI FINANCIAL CORP 1,370,648$88,037,0002.24%
Sonen Capital LLC 24,099$1,548,0002.21%
Foyston, Gordon, & Payne Inc 74,344$7,254,0002.10%
Ceredex Value Advisors LLC 2,137,537$138,047,0002.06%
Endurant Capital Management LP 89,863$5,772,0002.02%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q2 2022. To view BAXTER INTL INC's shareholder history, click here.